Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. NEJM. 2017;377:613–22.
1 Duley L. The global impact of preeclampsia and eclampsia. Semin Perinatol. 2009;33:130–7.
2 Ghossein-Doha C, van Neer J, Wissink B, Breetveld NM, de Windt LJ, van Dijk AP, et al. Preeclampsia, an important female specific risk factor for asymptomatic heart failure. UOG. 2017;49:143–9.
3 Sehqal A, Skilton MR, Crispi F. Human fetal growth restriction: a cardiovascular journey through to adolescence. J Dev Orig Health Dis. 2016;7:626–35.
4 Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy. Obstet Gynecol. 2010;116:402–14.
5 Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. AJOG. 2018;218:287–93.e1.
6 ACOG Committee Opinion No. 743: Low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;32:e44–e52.
7 National Institute of Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. Clinical Guideline CG107. January 2011.
9 Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8–15.
10 O’Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC. Study protocol for the randomized controlled trial: combined multimarker screening and randomized patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open. 2016;6:e011801.
11 O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. AJOG 2016; 214:103.e1–12.
12 Mosimann B, Pfiffner C, Amylidi-Mohr S, Risch L, Surbek D, Raio L. First trimester combined screening for preeclampsia and small for gestational age – a single centre experience and validation of the FMF screening algorithm. Swiss Med Wkly. 2017;147:w14498.
13 Guizani M, Valsamis J, Dutemeyer V, Kang X, Ceccotti V, Khalife J, Duiella SF, Blavier F, Faraca A, Cos T, Jani JC. First-trimester combined multimarker prospective sutdy fort he detection of preeclampsia at a high risk of developing preeclampsia using the Fetal Medicine Foundation-algorithm. Fetal Diagn Ther. 2018;43:266–73.
14 Skrastad RB, Hov GG, Blaas HG, Romundstad PR, Salvesen KA. Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms. BJOG. 2015;122:1781–8.
15 O’Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, et al. Accuracy of competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation. Ultrasound Obstet Gynecol. 2017;49:751–5.
16 Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for preeclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51:743–50.
17 Park FJ, Leung CH, Poon LC, Williams PF, Rothwell SJ, Hyett JA. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aust NZ J Obstet Gynecol. 2013;53:532–9.
18 Lobo GAR, Nowak PM, Panigassi AP, Lima AIF, Araujo Junior E, Nardozza LMM, Pares DBS. Validation of Fetal Medicine Foundation algorithm for prediction of preeclampsia in the first trimester in an unselected Brazilian population. J Matern Fetal Neonatal Med. 2017;19:1–7.
19 Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. NEJM. 2017;377:613–22.
20 Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, et al. ASPRE trial: incidence of preterm preeclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. UOG. 2018;51:738–42.
21 Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, et al. Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetric history. AJOG. 2017;217:585.e1–e5.
22 Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D, et al. Aspirin for evidence-based preeclampsia prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. AJOG. 2017;217:685.e1–e5.
23 Wright D, Rolnik DL, Syngelaki A, de Paco Matallana C, Machuca M, de Alvarado M, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit.AJOG. 2018;218:612.e1–e6.